Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $234000.0.

  • Centessa Pharmaceuticals' Capital Expenditures rose 58823.53% to $234000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $268000.0, marking a year-over-year increase of 33225.81%. This contributed to the annual value of $34000.0 for FY2024, which is 7988.17% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Capital Expenditures of $234000.0 as of Q3 2025, which was up 58823.53% from $34000.0 recorded in Q3 2024.
  • In the past 5 years, Centessa Pharmaceuticals' Capital Expenditures registered a high of $652000.0 during Q4 2022, and its lowest value of $10000.0 during Q2 2023.
  • In the last 4 years, Centessa Pharmaceuticals' Capital Expenditures had a median value of $65500.0 in 2023 and averaged $157400.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9570.55% in 2023, then skyrocketed by 58823.53% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Capital Expenditures (Quarter) stood at $652000.0 in 2022, then tumbled by 95.71% to $28000.0 in 2023, then rose by 21.43% to $34000.0 in 2024, then surged by 588.24% to $234000.0 in 2025.
  • Its last three reported values are $234000.0 in Q3 2025, $34000.0 for Q3 2024, and $28000.0 during Q4 2023.